The Technology Platform
Aadi Bioscience’s lead investigational drug candidate product nab-sirolimus leverages albumin-bound nanoparticle technology that is based on similar technology as ABRAXANE® (nab-paclitaxel; Abraxis Bioscience acquired by Celgene Corp in 2010)
Albumin is accumulated in tumor tissues, either due to the leaky capillary system and defective lymphatic drainage of tumors [1] or through an active gp60/caveolae-mediated transport process across tumor blood vessel endothelium [2, 3]. Importantly, albumin is taken up by proliferating tumor cells via endocytosis and macropinocytosis, then catabolized by lysosomal degradation to support de novo protein synthesis, energy, and tumor growth [4]. The accumulation of albumin in solid tumors provides potential rationale for albumin-based drug delivery systems to preferentially target tumors.
[1] Kratz F (2008). J Control Release 132, 171-183.
[2] Desai N et al (2006). Clin Cancer Res 12, 1317-1324.
[3] Minshall RD et al (2000). J Cell Biol 150, 1057-1070.
[4] Commisso C et al (2013). Nature 497, 633-637.
Preclinical Differentiation vs. Existing mTOR Inhibitors
In preclinical animal models, the nab technology investigational drug candidate nab-sirolimus has demonstrated advantages over existing mTOR inhibitors including:
